Oxtellar XR (Oxcarbazepine) Patent Expiration, LOE Window & CMS Spending

Oxtellar XR (Oxcarbazepine) by Supernus: FDA Orange Book LOE 2027-04-13, 3 AB generics, $90.9M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSupernus
FDA Application & PathwayN202810 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-04-13
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$90.9M
2024 Medicare Part D Spend$28.5M
2024 Medicaid Spend$62.4M
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 19.1% 2-yr change)